Clinical Lipidology Update 2025

For members of the Merck team attending the face-to-face meeting 2-3 December, 2025

Welcome to Clinical Lipidology Update for 2025

In this course, Faculty from the leadership of the European Atherosclerosis Society (EAS) present the latest developments in clinical lipidology and approaches to lipid management, bridging the gap between theory and real-world experience in lipid-lowering therapies.

Lipid-lowering treatments are key to preventing and managing atherosclerotic cardiovascular disease (ASCVD), one of the leading causes of illness and death worldwide.

Throughout the course, our experts will explore recent developments in research, updates in treatment guidelines, and illustrate their impact with patient-case studies.

Participants completing the course will have a clearer understanding of how lipid-lowering strategies are applied in everyday practice according to current guidelines, and improved confidence in discussions with physicians on recently published data.

The Scientific Director of the programme is former President of the EAS, Prof Lale Tokgozoglu, Ankara, Turkey.

The programme is in two parts:

Part 1: Available now. A short online curriculum of on-demand lectures for invited participants to work through prior to…
Part 2: A face-to-face meeting 2-3 December. Separate registration is required, invited participants only.

Sign in required.

At your own pace, work through these presentations to refresh your knowledge in the area in advance of the face-to-face meeting.

Ask the panel

During the face-to-face meeting there will be lots of opportunity to ask questions to the course faculty. If, while viewing the online presentations you think of questions that you’d like to put to the faculty, send them in advance.

Separate registration required, invited participants only.

Munich, Germany, 2-3 December, 2025

The full programme is as follows:

Day 1
13:00	Welcome, Introduction, housekeeping Lale Tokgozoglu, Turkey
13:10	Talk 1.1: Evolution of Guidelines from 4S onwards with respect to LDL-C treatment goals: Which landmark trials changed goals? The gap between guidelines goals and clinical practice Lale Tokgozoglu, Turkey Presentation, followed by Speaker Q&A
13:55	Break 5 min
14:00	Talk 1.2: Combination therapy – with case presentation Ulrich Laufs, Germany Presentation, followed by Speaker Q&A
14:45	Break 15 min
15:00	Talk 1.3: Implementation/quality in LDL-C lowering: How do we change the landscape? Kausik Ray, UK Presentation, followed by Speaker Q&A
15:45	Break 5 min
15:50	Talk 1.4: Lp(a) and remnant cholesterol in residual cardiovascular risk after LDL-C lowering Børge Nordestgaard, Denmark Presentation, followed by Speaker Q&A
16:35	Break 15 min
16:50	Talk 1.5: How to navigate when asked questions by physicians on newly presented data Børge Nordestgaard, Kausik Ray, Ulrich Laufs Presentation, followed by Speaker Q&A
17:35	Break 5 min
17:40	Panel Q&A
18:20	Wrap up Børge Nordestgaard, Denmark
18:30	Close

Day 2
08:00	Welcome, Introduction Ulrich Laufs, Germany
08:05	Talk 2.1 : How LDL-driven CV risk fits in the cardio-renal-metabolic axis (obesity) Nikolaus Marx, Germany Presentation, followed by Speaker Q&A
08:50	Talk 2.2: Can imaging help us quantify plaque burden and characteristics/vulnerability? Charalambas Antonoides, UK Presentation, followed by Speaker Q&A
09:35	Talk 2.3: New therapies: How will they change the landscape? Ulf Landmesser, Germany Presentation, followed by Speaker Q&A
10:20	Break 15 min
10:35	Introducing case studies: Treating the right patient at the right time: Erik Stroes, The Netherlands
10:40	Case 1: Presentation & discussion Alberto Zambon, Italy
11:05	Case 2: Presentation & discussion Erik Stroes, The Netherlands
11:30	Case 3: Presentation & discussion Alberto Zambon, Italy
11:55	Case 4: Presentation & discussion Erik Stroes, The Netherlands
12:20	Panel Q&A
12:50	Wrap up & Close Erik Stroes, The Netherlands

Course Learning Objectives:

Participants completing the course will have

a clearer understanding of how lipid-lowering strategies are applied in everyday practice according to current guidelines
improved confidence in discussions with physicians on recently published data

Faculty

Lale Tokgözoğlu	Professor of Cardiology, Hacettepe University Deputy Editor, European Heart Journal Former President, European Atherosclerosis Society
Kausik Ray	Professor of Public Health Honorary Consultant Cardiologist Director of ICTU-Global, Imperial Clinical Trials Unit NIHR ARC National Lead of Cardiovascular Disease Past President, European Atherosclerosis Society
Børge Nordestgaard	Professor and Chief Physician, Herlev og Gentofte Hospital, Copenhagen President, European Atherosclerosis Society
Ulrich Laufs	Professor and Chief of Cardiology at Leipzig University Hospital Executive Committee member, European Atherosclerosis Society
Nikolaus Marx	Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen, Germany
Charalambas Antonoides	Full Professor of Cardiovascular Medicine at the University of Oxford and a Consultant Cardiologist in Oxford University Hospitals.
Ulf Landmesser	Professor at the Institute for Health Research in Berlin and Head of the Medical Clinic of Cardiology at the Charité in Berlin
Alberto Zambon	Associate Professor of Medicine, Department of Medicine, University of Padua School of Medicine, Italy Affiliate Assistant Professor, of Medicine, Division of Endocrinology, Metabolism and Nutrition, School of Medicine, University of Washington, Seattle, USA
Erik Stroes	Principal Investigator, Prof. MD PhD Full Professor, Experimental Vascular Medicine Full Professor, Vascular Medicine, Academic Medical Centre, Amsterdam